T. Rowe Price Associates’s Health Catalyst HCAT Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $311K | Buy |
82,328
+7,122
| +9% | +$26.9K | ﹤0.01% | 2511 |
|
2025
Q1 | $341K | Buy |
75,206
+12,763
| +20% | +$57.9K | ﹤0.01% | 2409 |
|
2024
Q4 | $442K | Buy |
62,443
+4,798
| +8% | +$34K | ﹤0.01% | 2326 |
|
2024
Q3 | $470K | Buy |
57,645
+557
| +1% | +$4.54K | ﹤0.01% | 2270 |
|
2024
Q2 | $365K | Buy |
57,088
+7,342
| +15% | +$46.9K | ﹤0.01% | 2320 |
|
2024
Q1 | $375K | Buy |
49,746
+2,831
| +6% | +$21.3K | ﹤0.01% | 2326 |
|
2023
Q4 | $435K | Buy |
46,915
+4,941
| +12% | +$45.8K | ﹤0.01% | 2233 |
|
2023
Q3 | $425K | Buy |
41,974
+1,541
| +4% | +$15.6K | ﹤0.01% | 2189 |
|
2023
Q2 | $506K | Buy |
40,433
+676
| +2% | +$8.46K | ﹤0.01% | 2119 |
|
2023
Q1 | $464K | Buy |
39,757
+970
| +3% | +$11.3K | ﹤0.01% | 2146 |
|
2022
Q4 | $412K | Buy |
38,787
+3,613
| +10% | +$38.4K | ﹤0.01% | 2223 |
|
2022
Q3 | $342K | Buy |
35,174
+8,887
| +34% | +$86.4K | ﹤0.01% | 2315 |
|
2022
Q2 | $381K | Buy |
26,287
+5,804
| +28% | +$84.1K | ﹤0.01% | 2329 |
|
2022
Q1 | $535K | Buy |
20,483
+5,142
| +34% | +$134K | ﹤0.01% | 2298 |
|
2021
Q4 | $608K | Sell |
15,341
-664
| -4% | -$26.3K | ﹤0.01% | 2298 |
|
2021
Q3 | $800K | Buy |
16,005
+491
| +3% | +$24.5K | ﹤0.01% | 2147 |
|
2021
Q2 | $861K | Buy |
15,514
+1,431
| +10% | +$79.4K | ﹤0.01% | 2128 |
|
2021
Q1 | $659K | Buy |
14,083
+13
| +0.1% | +$608 | ﹤0.01% | 2230 |
|
2020
Q4 | $612K | Sell |
14,070
-170,213
| -92% | -$7.4M | ﹤0.01% | 2162 |
|
2020
Q3 | $6.75M | Sell |
184,283
-156,607
| -46% | -$5.73M | ﹤0.01% | 1366 |
|
2020
Q2 | $9.94M | Sell |
340,890
-134,384
| -28% | -$3.92M | ﹤0.01% | 1297 |
|
2020
Q1 | $12.4M | Buy |
475,274
+194,037
| +69% | +$5.07M | ﹤0.01% | 1190 |
|
2019
Q4 | $9.76M | Sell |
281,237
-19,499
| -6% | -$677K | ﹤0.01% | 1316 |
|
2019
Q3 | $9.52M | Buy |
+300,736
| New | +$9.52M | ﹤0.01% | 1300 |
|